ARSENAL MEDICAL INC
Watertown, MA · Founded 2011 · CIK 0001528846 · Medtech · Private
Embolic and hemorrhage control devices for neurovascular and trauma interventions
arsenalmedical.com →- Grants
- $8.1M
- 10 awards
- Sector median: 1
- Raised
- $16M
- 5 Form D · Jun 2019
- 87 months since last filing
- Contracts
- $44M
- 3 awards · Defense
- #21 of 4531 in medtech
- Patents
- 25
- 15 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Federal contract | Department of Defense · Research Contract | $15,010,150 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Private capital raised | Form D · SEC | $4,000,000 | |
| Federal contract | Department of Defense · Injectable Hemostatic Prototypes | $207,400 | |
| Federal contract | Department of Defense · Igf::ot::igf Pre-fda Approval | $28,358,509 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Self-Expanding Foams for Percutaneous Damage Control of Retroperitoneal Pelvic Exsanguination | $227,667 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Self-Expanding Foams for Percutaneous Damage Control of Retroperitoneal Pelvic Exsanguination | $762,094 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Self-Expanding Foams for Percutaneous Damage Control of Retroperitoneal Pelvic Exsanguination | $1,524,188 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Self-Expanding Foams for Percutaneous Damage Control of Retroperitoneal Pelvic Exsanguination | $762,094 | |
| Private capital raised | Form D · SEC | $6,017,967 | |
| Federal grant | Department of Health and Human Services · Phase I · Ideal Embolic for Portal Vein Embolization | $367,201 | |
| Federal grant | Department of Health and Human Services · Phase I · Ideal Embolic for Portal Vein Embolization | $367,201 | |
| Federal grant | Department of Health and Human Services · Phase II · Flow Responsive Embolic Agent for the Complete Devascularization of Meningiomas | $791,378 | |
| Federal grant | Department of Health and Human Services · Phase II · Flow Responsive Embolic Agent for the Complete Devascularization of Meningiomas | $1,908,752 | |
| Federal grant | Department of Health and Human Services · Phase II · Flow Responsive Embolic Agent for the Complete Devascularization of Meningiomas | $1,117,374 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering a Middle Meningeal Artery Embolization Model with Hydrophilicity and Hydraulic Resistance | $314,363 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 18 | Tempus AI | $51M | — |
| 19 | SIMETRI, INC. | $50M | — |
| 20 | ROTECH HEALTHCARE INC | $47M | $6.5M |
| 21 | ARSENAL MEDICAL INC | $44M | $16M |
| 22 | MBIO DIAGNOSTICS INC | $42M | — |
| 23 | LUMINOSTICS INC | $41M | — |
| 24 | Zebra Imaging, Inc. | $41M | $8.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James BarryExecutive Officer
- Jim BarryExecutive Officer
- Earl CollierDirector · Executive Officer
- Dennis DoughertyDirector
- Thomas FitzgeraldExecutive Officer
- James GoldsteinDirector
- Jamie GoldsteinDirector
- Robert LangerDirector
- Terrance McGuireDirector
- Terry McGuireDirector
- Richard MottDirector
- Guido NeelsDirector
- Carmichael RobertsDirector
- James RosenDirector
- Upma SharmaExecutive Officer
- George WhitesidesDirector
Patents
- Embolic Compositions And Methodsapplication
- In Situ Forming Hemostatic Foam Implantsgranted
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
- Medical Deviceapplication
- Embolic Compositions And Methodsgranted
- Embolic Compositions And Methodsgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.